The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1702
May 13, 2024
View Complete Issue         Table of Contents 2019 
A New Indication for Bempedoic Acid (Nexletol)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Indication for Bempedoic Acid (Nexletol)
May 13, 2024 (Issue: 1702)
The oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid was approved by the FDA in 2020 for use alone (Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Indication for Bempedoic Acid (Nexletol)
Article code: 1702b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.